NICE issues schizophrenia commissioning guide
pharmafile | January 14, 2010 | News story | | NICE, commissioning, schizophrenia
NICE has published a commissioning guide to help primary and secondary care teams recognise, treat and manage adult schizophrenia.
The guide will help healthcare professionals by “providing key clinical and service-related issues to consider during the commissioning process”.
It provides PCTs with a new tool to identify local service requirements, review current services and highlight future needs, and identifies specific areas of clinical practice that should be adopted.
Schizophrenia is one of the most common of the serious mental health disorders but can often be misunderstand and susceptible to considerable stigma and a limited understanding.
According to one report, as many as one in 100 people can experience at least one episode of acute schizophrenia in their lifetime. Both men and women are equally affected, but men are more susceptible between the ages of 15-30 and women between 25–30.
NICE has also issued a commissioning guide for the diagnosis and management of rheumatoid arthritis in adults as well as updating 28 existing commissioning guides.
The two new guides ‘Service for the treatment and management of schizophrenia in adults’ and ‘Service for the diagnosis and management of rheumatoid arthritis in adults’, along with the updated guides can be accessed here.
Related Content

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan
EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical …

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …





